Various factors have been implicated in ovarian aging and the winding-down of a woman's fertility, including oxidative damage and the accumulation of DNA breaks in reproductive cells. A new study suggests that apoptosis of damaged cells is mediated by a key regulator of protein synthesis, EEF2K (eukaryotic elongation factor-2 kinase). EEF2K is involved in killing ovarian follicles destined for atresia, during which unused ovarian follicles degenerate and are resorbed prior to ovulation of the single surviving oocyte.
Cell death has previously been implicated in oocyte fitness. For instance, C. elegans mutations that prevent cell death result in a dramatic decline in oocyte quality. In mammals, about 99.9 percent of the cells in the female germ line undergo apoptosis-females start out life with millions of primordial oogonia, but most eventually die. Women ovulate only several hundred oocytes in a lifetime.
Hsueh-Ping Chu et al. delved into the question of what determines whether germ cell-bearing mouse follicles die or survive. They landed on EEF2K, an evolutionarily conserved regulator of protein synthesis. EEF2K phosphorylates EEF2 (eukaryotic elongation factor 2), resulting in arrest of mRNA translation. The researchers found that EEF2K is expressed at high levels in the follicles of mice and in the germline of C. elegans, and it seems to sensitize germ cells of both species to apoptosis. Cells that are damaged by oxidative stress, for instance, were shown to die via an EEF2K-mediated mechanism.
The researchers showed that mice and worms deficient in EEF2K have reduced apoptosis in the ovary, and the worms display an increase in poor-quality oocytes. In the EEF2K-deficient mouse, for instance, these oocytes are more resistant to apoptosis induced by oxidative stress. Compared with wild-type mice, EEF2K-deficient mice are able to become pregnant at an older age, but they do not deliver viable pups, suggesting that oocyte survival is not sufficient to assure oocyte quality.
The researchers propose that EEF2K-mediated inhibition of protein synthesis may lower the threshold for triggering apoptosis. Through this mechanism, EEF2K reveals and eliminates oocytes with defects.
Exactly how EEF2K sensitizes germ cells to apoptosis is unclear. However, the researchers showed that, as part of its global lockdown on protein synthesis, EEF2K down-regulates two key anti-apoptotic proteins. Regular reproductive cycles, the menstrual cycle in primates and the estrous cycle in other species, are a key evolutionary innovationthey enable females to conceive only a few young at a time, thereby conserving resources and maximizing survival of offspring. Tight control of the estrous cycle requires precise regulation of hormones and their production, such as properly timed production of LH (luteinizing hormone) to trigger ovulation. New findings showcase how LH and a related hormone, FSH (follicle-stimulating hormone), escape the pituitary gland through distinct mechanisms that affect the timing of hormone release. The results provide insight into hormone regulation and fodder for speculation about the evolution of the estrous cycle.
Some primitive vertebrates have only one gonadotropin: a hormone (secreted from the pituitary) that controls ovulation; many of these species release their eggs by spawning, in a single massive burst. But higher vertebrates have two such hormones-LH, and its closely related hormone FSH. FSH is released through a constitutive mechanism whereas LH is released in a pulsatile fashion, with a wellknown surge that provokes ovulation in the follicle that has been primed by FSH and estrogens. Very little is known about the molecular basis for the different patterns of release of these two gonadotropic hormones.
In previous studies, T. Rajendra Kumar and colleagues suggested that the secretion pattern of LH is controlled by a small peptide-a short, 7-amino acid motif present on the carboxy terminal of one of its two subunits. This peptide shunts LH into a secretion pathway that involves release from granules stored under the membrane. In the new study, the researchers engineered human FSH to express this peptide, and expressed the transgene in mice lacking wild-type FSH.
The researchers found that the transgenic FSH was directed into the LH secretion pathway-having been spewed from granules. The transgenic mice also were hyper-fertile. They produced an average of 55 eggs per cycle, compared with 9 in wild-type controls, and had an extended reproductive lifespan, with older transgenic mice producing more eggs than similarly aged, wild-type mice. No differences in the numbers of primordial or growing follicles were observed. Instead, the hyper-fertile and extended reproductive-lifespan phenotypes were traced to a reduction in atresia-the process by which unused ovarian follicles degenerate on a regular basis.
The researchers also showed that the extra eggs from the transgenic mice seemed to be of high quality and developed into blastocysts in vitro. When one-cell embryos derived from natural matings were put into recipient wild-type mothers, they yielded high numbers of pups.
The researchers propose that the two hormones help keep vertebrate fertility under control. It is well known that adding exogenous FSH or FSH-like hormones in mammals increases the ovulatory rate. The researchers suggest that FSH, constitutively secreted, acts to regulate follicle development, thereby maintaining low levels of follicle survival and ensuring that most eggs die off through atresia. A surge of LH causes the release of the surviving eggs. The whole system assures carefully calibrated maturation of a controlled number of eggs through the estrous cycle, maintaining the monovular pattern that characterize some species and the polyovular pattern present in others. Sperm in the testis develop in tiny ''nursing pockets'' between Sertoli cells, with each Sertoli cell nurturing dozens of germ cells. As germ cells mature during spermiogenesis, they migrate from the basal portion of the seminiferous tubule to the luminal side. This transition from a haploid round germ cell to a completed spermatozoon ends with release into the lumen.
Researchers have now identified a molecule key to this maturation process-TAp73. TAp73 is made in germ cells and seems to coordinate transcription of various adhesion and migration proteins; these proteins in turn mediate germ cell attachment to and migration through the supporting Sertoli cells. TAp73 is a cousin to TAp63 and p53, the ''guardian of the genome,'' and these new findings broaden the role for this gene family in the germ line.
Previous studies have shown that TAp63 is the primary protector of germline integrity in mice and humans: it is highly expressed in both male and female germ cells, and is activated by DNA damage. Once activated, it eliminates damaged cells through apoptosis. p53 apparently plays a role in both sexes by helping TAP63 to eliminate damaged sperm in the adult.
In female mice, TAp73 has been shown to have a protective roleaffecting spindle dynamics in oocytes and egg ovulation. Although TAp73-deficient males are infertile, the molecular role of TAp73 in males has been unknown.
In the new study, Lena Holembowski et al. found that developing germ cells of TAp73-deficient mice prematurely detach from Sertoli cells, after which they die by apoptosis. TAp73 was found to control a broad transcriptional program for various genes involved in adhesion and migration, such as integrins and proteases. As a collateral consequence of this gene dysregulation, Sertoli cells also degenerated and the blood-testis barrier became leaky.
The findings showcase how each of the three p53 family members has a distinct role in germline development, and serve to expand their roles beyond the family's well-known occupation as tumor suppressors. A long-sought partner for an egg-binding protein on the surface of mammalian sperm has been identified by Gavin Wright's lab. The egg protein, dubbed JUNO for the Roman goddess of fertility, mediates fertilization and seems to be central to the mechanism that prevents multiple sperm from entering the egg.
For years, IZUMO1, a protein on the surface of sperm, has been known to mediate fertilization. Named after a Japanese marriage shrine, IZUMO1 binds to the surface of the egg, but the molecule to which it binds has been elusive.
Suspecting that the interaction between the two proteins was weak, as with many membrane-embedded proteins, Wright et al. deployed methods they had developed previously to identify such weakly interacting partners. The researchers generated an IZUMO1-binding probe with a method that caused the extracellular regions of the protein to oligomerize, strengthening transient protein interactions.
Using an oocyte cDNA library to select proteins that bound to this cellular probe, the researchers pulled out JUNO. JUNO is known to be expressed on regulatory T cells; it is encoded by a gene originally named folate receptor paralog (Folr4). Wright and colleagues found that the protein could not bind folate, and proposed renaming it JUNO.
The researchers found that JUNO was expressed on the oocyte surface (see Fig. 1 ) and was required for IZUMO1 binding. Moreover, female mice deficient in JUNO1 were infertile. Deficiency of another protein, the tetraspanin CD9, results in poor female fertility, and the researchers speculate that CD9 may help oligomerize JUNO1 on the oocyte surface.
JUNO1 also seems to be central to the first phase of the block to polyspermy. Very little is known about this phase, except that it involves changes ithe oocyte membrane and is complete in 30-45 minutes. It differs from the second phase, where the zona pellucida hardens. The researchers found that JUNO expression rapidly faded after fertilization, and was barely detectable 30-40 minutes later. Curiously, instead of being absorbed by the egg, JUNO seemed to be expelled in extracellular vesicles. The authors speculate that these extracellular vesicles might serve as egg decoys to soak up additional incoming sperm after conception.
The binding interaction between JUNO and IZUMO1 was conserved in humans, pigs, and opossums, strengthening the potential for the findings to be exploited for the development of non-hormonal contraceptives. Events during fetal life can influence testosterone levels in adulthood, but the mechanism for this connection has been elusive. Karen Kilcoyne et al. now identify stem cells in the fetal testis that respond to fluctuations in testosterone levels and may account for this effect. In adults, testosterone is produced by Leydig cells in the testis. Since adult-type Leydig cells do not differentiate until puberty, researchers have been at a loss to explain how testosterone production can be influenced by fetal events, such as reduced fetal androgen exposure. The researchers hypothesized that stem cells for adult Leydig cells must be present in the fetal testes.
The researchers built on previous studies showing that a specific gene, Coup-tfII (chicken ovalbumin upstream promotor transcription factor II, an orphan nuclear receptor also known as Nr2f2), was necessary for Leydig cells to develop. They showed that COUP-TFII served as a marker for the fetal stem cells that give rise to adult Leydig cells. COUP-TFII-expressing cells were abundant in the fetal testis of both humans and rodents. And, when they ablated Leydig cells in adult rats, the cells were repopulated from a set of COUP-TFIIexpressing cells.
The researchers went on to show that reductions in fetal androgen could affect the programming of these stem cells in rodents. They manipulated androgen action either genetically or through exposing fetuses in utero to dibutyl-phthalate, which reduced fetal testosterone.
As a result, animals were born with reduced numbers of these stem cells, and the resulting adult males had low testosterone levels.
The researchers showed that, in these animals, the stem cells as well as the adult Leydig cells had increased levels of a histone modification involved in methylation, H3K27me3. Moreover, the promoter of a gene central to testosterone production, StAR (steroidogenic acute regulatory protein), was also highly methylated, lowering its expression.
The results hint at a biological basis for a host of troubling epidemiological observations. These include Northern European studies showing low sperm count in one in six young men, and a decline in testosterone levels in men of all ages-although many links are missing in establishing the chain from fetal stem Leydig cells to these epidemiological findings. 
